Latest From Cel-Sci Corp.
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
The biggest Phase III trial in head and neck cancer is resuming after the FDA lifted a freeze on trials evaluating CEL-SCI's lead asset Multikine in the indication, giving a boost to its commercial prospects.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Cel-Sci Corp.
- Senior Management
Geert R Kersten, CEO
Eyal Talor, PhD, CSO
Todd S Burkhart, VP, Mfg./Facilities & Commercial Ops.
- Contact Info
Phone: (703) 506-9460
8229 Boone Blvd.
Vienna, VA 22182
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.